The globally pioneering drug has entered Phase II clinical trials, and the Life and Health Research Institute has been established in Guangzhou to advance technology R&D and industrialization bases... Recent continuous announcements from Youngy Group indicate that the biopharmaceutical-related industry will serve as another new growth engine for the group.

Among numerous innovative sectors, Youngy Group has chosen the life science and technology industry. Xie Yegen, a director of Youngy Group, revealed that this is a scientific decision made by the group's Chairman Lv Xiangyang based on long-term strategic considerations and the group's own strengths. Youngy Group will integrate its management, capital, and operational advantages to build a life and health R&D and industrialization platform, leading the development of the industry.

Currently, Youngy Group has established a Biomedical Research Institute in Nanjing and a Life and Health Research Institute in Guangzhou, dedicated to establishing a complete chain from basic scientific discoveries and key technological breakthroughs to early-stage industrial application incubation.

Meanwhile, Youngy Group's bispecific antibody drug, which possesses complete intellectual property rights, has also made new progress and has entered Phase II clinical trials.

It is reported that Youngy Group places great emphasis on the core role of talent in life science and technology innovation. Through a series of operational entities and incentive designs, the group is creating a platform where it shares risks and rewards with scientists, attracting top scientists from around the world to collaborate.

Shi Lv, General Manager of Guangzhou Youngy Life and Health Research Institute (hereinafter referred to as the "Institute"), stated that the Life and Health Research Institute, officially established this year, is positioned as the group's original technology hub and a driver for the transformation of research achievements. It focuses on cutting-edge areas such as cell therapy, gene technology, neuroscience, and AI-driven drug development.

Currently, the Institute is vigorously recruiting high-end talent and assembling R&D teams. According to the plan, the group will invest substantial funds over the next three years to actively advance the construction of 30 to 40 R&D pipelines. At that time, it will also actively explore the integration path of "AI + life sciences," leveraging artificial intelligence technology for target discovery, drug design, and clinical prediction.

Youngy Group stated that it will strive to forge a unique path of innovation, provide sustainable health solutions, and create a new paradigm for the deep integration of "capital + industry."